December 4, 2012
InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard™ Embolic Protection Stent (EPS), will sponsor a satellite symposium on
at the ICI, Innovations in Cardiovascular Innovation, Meeting at the David Intercontinental Hotel, Tel-Aviv.
InspireMD's symposium will be chaired by Dr.
Gregg W. Stone
, and the meeting faculty includes Drs.
. The session, titled "MGuard Embolic Protection Stent (EPS) Outperforms BMS and DES in STEMI Treatment", will show the 30 days MASTER trial randomized data of MGuard in STEMI patients, as well challenging cases that give insights into the uses and benefits of the MGuard MicroNet® EPS technology.
The MASTER trial findings were presented for the first time at the Late Breaking Clinical Trials session of the 24th Annual Transcathater Cardiovascular Therapeutics (TCT) scientific meeting in
. The results showed the novel MGuard EPS provided a statistically and clinically significant acute advantage and, as a result, may hold the potential to lower the incidence of adverse sequela and prolong survival of heart attack victims.
The MASTER trial randomized 432-patient data was published in the
November 6, 2012
print edition of the peer-reviewed
Journal of American College of Cardiology,
Vol. 60, No. 19.
The online version of the paper, authored by
Gregg W. Stone
, MD and others, appeared Wednesday (
, coinciding with Dr. Stone's presentation of the findings at TCT.
About Stenting and MGuard EPS
Standard stents weren't engineered for heart attack patients. They were designed for treating stable angina patients whose occlusion is different from that of an occlusion in a heart attack patient.